João Miguel Frazão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
João Miguel Frazão has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Teresa Adragão
Hospital de Santa Cruz, Portugal
8 shared publications Jack W. Coburn
5 shared publications- Catarina Carvalho
Nephrology and Infectious Diseases Research Group, Institute for Innovation and Health Research (I3S), Institute of Biomedical Engineering (INEB), University of Porto, 4200-135 Porto, Portugal
3 shared publications Luciano Pereira
University of Porto
3 shared publications- Abílio José Borges Silva
DaVita Portugal, Portugal
2 shared publications - Aníbal Ferreira
Nephrology Department, Hospital Curry Cabral, Unidade Local de Saúde São José, Lisbon, Portugal
2 shared publications
Latest Publications
- Open Access
- 16 December 2024
- Published by Health Sciences Research Unit: Nursing in Revista de Enfermagem Referência
- Vol. VI Série (N.º 3)
Literacia em saúde na pessoa com doença renal crónica em programa regular de hemodiálise
Enquadramento: O aumento da prevalência da doença renal crónica nos últimos anos levou ao seu reconhecimento como um problema de saúde pública, enquanto a literacia em saúde ganhou destaque no campo da saúde pública Objetivo: Avaliar a literacia em saúde na pessoa com doença renal crónica em programa regular de hemodiálise. Metodologia: Estudo de abordagem quantitativa, descritivo transversal usando a versão portuguesa do European Health Literacy Survey (HLS-EU-PT). A amostra incluiu 268 doentes com idades compreendidas entre os 25 e os 90 anos, em sete clínicas de Portugal continental. Resultados: Observamos que 74% da nossa amostra apresentava literacia em saúde limitada. Além disso, verificou-se que as habilitações académicas (p < 0,001) e a idade (p < 0,001) estavam significativamente associadas aos níveis de literacia. Na análise do HLS-EU-PT aplicado à nossa amostra, todos os índices apresentaram scores inferiores e com relevância estatística quando comparados à restante população portuguesa. Conclusão: Ficou evidente a necessidade de desenvolver estratégias eficazes para melhorar os níveis de literacia em saúde em pessoas com insuficiência renal.
- 16 December 2024
- Published by Health Sciences Research Unit: Nursing in Revista de Enfermagem Referência
- Vol. VI Série (N.º 3)
Open AccessLiteracia em saúde na pessoa com doença renal crónica em programa regular de hemodiálise
Enquadramento: O aumento da prevalência da doença renal crónica nos últimos anos levou ao seu reconhecimento como um problema de saúde pública, enquanto a literacia em saúde ganhou destaque no campo da saúde pública Objetivo: Avaliar a literacia em saúde na pessoa com doença renal crónica em programa regular de hemodiálise. Metodologia: Estudo de abordagem quantitativa, descritivo transversal usando a versão portuguesa do European Health Literacy Survey (HLS-EU-PT). A amostra incluiu 268 doentes com idades compreendidas entre os 25 e os 90 anos, em sete clínicas de Portugal continental. Resultados: Observamos que 74% da nossa amostra apresentava literacia em saúde limitada. Além disso, verificou-se que as habilitações académicas (p < 0,001) e a idade (p < 0,001) estavam significativamente associadas aos níveis de literacia. Na análise do HLS-EU-PT aplicado à nossa amostra, todos os índices apresentaram scores inferiores e com relevância estatística quando comparados à restante população portuguesa. Conclusão: Ficou evidente a necessidade de desenvolver estratégias eficazes para melhorar os níveis de literacia em saúde em pessoas com insuficiência renal.
- Open Access
- 11 November 2024
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 40 (5) , 831-832
In memoriam—Fernando José Carrera Carbó (1944–2024)
João M Frazão; In memoriam - Fernando José Carrera Carbó (1944–2024), Nephrology Dialysis Transplantation, , gfae246, https://doi.org/10.1093/ndt/gfae246
- 11 November 2024
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 40 (5) , 831-832
Open AccessIn memoriam—Fernando José Carrera Carbó (1944–2024)
João M Frazão; In memoriam - Fernando José Carrera Carbó (1944–2024), Nephrology Dialysis Transplantation, , gfae246, https://doi.org/10.1093/ndt/gfae246
- Open Access
- 1 January 2023
- Published by Health Sciences Research Unit: Nursing in Revista de Enfermagem Referência
- Vol. VI Série (Nº2) , 1-10
Qualidade de vida na pessoa com insuficiência renal crónica em programa regular de hemodiálise
Background: The number of people suffering from chronic kidney disease undergoing hemodialysis in Portugal has been increasing over the last decade, highlighting the need to assess the quality of life of these patients. Objective: To assess the quality of life of patients with chronic kidney disease undergoing regular hemodialysis. Methodology: A quantitative, cross-sectional descriptive study was conducted using the Kidney Disease Quality of Life Instrument (KDQOL-SF Version 1.3). The non-probability convenience sample consists of 268 patients aged 25 to 90 years undergoing regular hemodialysis in seven clinics in Portugal. Results: The Dialysis staff encouragement (82.46) and social support (77.49) dimensions had the highest scores. Male patients had higher scores in the physical functioning (p = 0.023), bodily pain (p = 0.011), and emotional well-being (p = 0.020) dimensions. This sample had statistically significan lower scores in all domains of the 36-Item Health Survey (SF-36) than the general Portuguese population. Conclusion: It is essential to develop strategies to improve the quality of life of patients with chronic kidney disease. Marco contextual: En la última década ha aumentado el número de personas con insuficiencia renal crónica que se someten a un programa de hemodiálisis, lo que plantea la necesidad de evaluar la calidad de vida de estos pacientes. Objetivo: Evaluar la calidad de vida de los pacientes renales crónicos en programa regular de hemodiálisis. Metodología: Se trata de un estudio cuantitativo, transversal y descriptivo que utiliza el KDQOL-SF. Muestra de conveniencia no probabilística, con 268 pacientes en programa regular de hemodiálisis con edades comprendidas entre los 25 y los 90 años, en siete clínicas de Portugal. Resultados: La motivación del personal de diálisis (82,46) y el apoyo social (77,49) fueron las dimensiones con las mejores puntuaciones. Los individuos del sexo masculino presentan mejores puntuaciones en calidad de vida, en las dimensiones: función física (p = 0,023), dolor (p = 0,011) y bienestar emocional (p = 0,020). El análisis del SF-36 demostró que todos los dominios presentaban una puntuación peor y con significación estadística en comparación con la población portuguesa. Conclusión: Es esencial idear estrategias que puedan mejorar la calidad de vida de las personas com insuficiencia renal. Enquadramento: Ao longo da última década observou-se um aumento no número de pessoas que sofrem de doença renal crónica em programa de hemodiálise, imergindo a necessidade de aferir a qualidade de vida destes doentes. Objetivo: Avaliar a qualidade de vida dos doentes renais crónicos em programa regular de hemodiálise. Metodologia: Estudo de abordagem quantitativa, descritivo transversal utilizando o KDQOL-SF.Amostra não probabilística de conveniência, com 268 doentes em programa regular de hemodiálise com idades entre 25 e 90 anos, em sete clínicas de Portugal. Resultados: O encorajamento do pessoal da diálise (82,46) e o apoio social (77,49) foram as dimensões com melhores scores. Os indivíduos do sexo masculino apresentam melhores pontuações na qualidade de vida, nas dimensões: função física (p = 0,023), dor (p = 0,011) e bem-estar emocional (p = 0,020). A análise do SF-36 demostrou que todos os domínios apresentavam pior score e com significado estatístico quando comparados com a população portuguesa. Conclusão: É fundamental arranjar estratégias que possam melhorar qualidade de vida da pessoa com insuficiência renal.
- 1 January 2023
- Published by Health Sciences Research Unit: Nursing in Revista de Enfermagem Referência
- Vol. VI Série (Nº2) , 1-10
Open AccessQualidade de vida na pessoa com insuficiência renal crónica em programa regular de hemodiálise
Background: The number of people suffering from chronic kidney disease undergoing hemodialysis in Portugal has been increasing over the last decade, highlighting the need to assess the quality of life of these patients. Objective: To assess the quality of life of patients with chronic kidney disease undergoing regular hemodialysis. Methodology: A quantitative, cross-sectional descriptive study was conducted using the Kidney Disease Quality of Life Instrument (KDQOL-SF Version 1.3). The non-probability convenience sample consists of 268 patients aged 25 to 90 years undergoing regular hemodialysis in seven clinics in Portugal. Results: The Dialysis staff encouragement (82.46) and social support (77.49) dimensions had the highest scores. Male patients had higher scores in the physical functioning (p = 0.023), bodily pain (p = 0.011), and emotional well-being (p = 0.020) dimensions. This sample had statistically significan lower scores in all domains of the 36-Item Health Survey (SF-36) than the general Portuguese population. Conclusion: It is essential to develop strategies to improve the quality of life of patients with chronic kidney disease. Marco contextual: En la última década ha aumentado el número de personas con insuficiencia renal crónica que se someten a un programa de hemodiálisis, lo que plantea la necesidad de evaluar la calidad de vida de estos pacientes. Objetivo: Evaluar la calidad de vida de los pacientes renales crónicos en programa regular de hemodiálisis. Metodología: Se trata de un estudio cuantitativo, transversal y descriptivo que utiliza el KDQOL-SF. Muestra de conveniencia no probabilística, con 268 pacientes en programa regular de hemodiálisis con edades comprendidas entre los 25 y los 90 años, en siete clínicas de Portugal. Resultados: La motivación del personal de diálisis (82,46) y el apoyo social (77,49) fueron las dimensiones con las mejores puntuaciones. Los individuos del sexo masculino presentan mejores puntuaciones en calidad de vida, en las dimensiones: función física (p = 0,023), dolor (p = 0,011) y bienestar emocional (p = 0,020). El análisis del SF-36 demostró que todos los dominios presentaban una puntuación peor y con significación estadística en comparación con la población portuguesa. Conclusión: Es esencial idear estrategias que puedan mejorar la calidad de vida de las personas com insuficiencia renal. Enquadramento: Ao longo da última década observou-se um aumento no número de pessoas que sofrem de doença renal crónica em programa de hemodiálise, imergindo a necessidade de aferir a qualidade de vida destes doentes. Objetivo: Avaliar a qualidade de vida dos doentes renais crónicos em programa regular de hemodiálise. Metodologia: Estudo de abordagem quantitativa, descritivo transversal utilizando o KDQOL-SF.Amostra não probabilística de conveniência, com 268 doentes em programa regular de hemodiálise com idades entre 25 e 90 anos, em sete clínicas de Portugal. Resultados: O encorajamento do pessoal da diálise (82,46) e o apoio social (77,49) foram as dimensões com melhores scores. Os indivíduos do sexo masculino apresentam melhores pontuações na qualidade de vida, nas dimensões: função física (p = 0,023), dor (p = 0,011) e bem-estar emocional (p = 0,020). A análise do SF-36 demostrou que todos os domínios apresentavam pior score e com significado estatístico quando comparados com a população portuguesa. Conclusão: É fundamental arranjar estratégias que possam melhorar qualidade de vida da pessoa com insuficiência renal.
- 12 September 2022
- Published by S. Karger AG in Nephron
- Vol. 147 (3-4) , 158-169
Lessons from Four Decades of Systemic Amyloidosis with Renal Involvement
Background: Apart from ATTR amyloidosis, the epidemiology and outcomes of the most common subtypes of systemic amyloidosis in Portugal remain primarily unknown. Methods: This retrospective cohort study evaluated patients with renal biopsy-proven amyloidosis, diagnosed from January 1978 to December 2019. Follow-up started at kidney disease presentation and ended at death or August 2020. Clinical presentation, survival, and prognostic factors were analysed. Results: Of 123 patients with amyloid nephropathy, 111 had definite amyloid typing and were analysed. AA amyloidosis was the most frequent type (56.1%) and was related mainly to chronic infection (47.8%) and chronic inflammatory arthritis (29.0%). AL amyloidosis was present in 25.2% of patients and hereditary forms in 6.5% (4.1% AFibE526V, 2.4% ATTRV30M). During follow-up, 73.9% of AA and 54.8% of AL patients progressed to end-stage renal disease, and 79.7% of AA and 77.4% of AL died; median overall survival was 66.0 (95% CI, 33.0–99.0) and 18.0 (95% CI, 9.3–26.7) months (p = 0.025), respectively. There were no significant differences in renal outcome and survival on dialysis between these two types. In multivariate analysis, cardiac involvement at presentation (HR 6.26 [95% CI, 2.89–13.56]) and estimated glomerular filtration rate 2 (HR 2.05 [95% CI, 1.06–3.99]) independently influenced AA and AL amyloidosis survival. Cardiac involvement at presentation was an independent predictor of death (HR 9.65 [95% CI, 2.91–31.95]) and early mortality in AL amyloidosis. Conclusions: In Portugal, AA amyloidosis and related chronic infections are still relevant. Regarding AL amyloidosis, the low incidence and advanced disease at presentation result from missed and erroneous diagnoses, leading to delayed referrals and poor outcomes in these patients.
- 12 September 2022
- Published by S. Karger AG in Nephron
- Vol. 147 (3-4) , 158-169
Lessons from Four Decades of Systemic Amyloidosis with Renal Involvement
Background: Apart from ATTR amyloidosis, the epidemiology and outcomes of the most common subtypes of systemic amyloidosis in Portugal remain primarily unknown. Methods: This retrospective cohort study evaluated patients with renal biopsy-proven amyloidosis, diagnosed from January 1978 to December 2019. Follow-up started at kidney disease presentation and ended at death or August 2020. Clinical presentation, survival, and prognostic factors were analysed. Results: Of 123 patients with amyloid nephropathy, 111 had definite amyloid typing and were analysed. AA amyloidosis was the most frequent type (56.1%) and was related mainly to chronic infection (47.8%) and chronic inflammatory arthritis (29.0%). AL amyloidosis was present in 25.2% of patients and hereditary forms in 6.5% (4.1% AFibE526V, 2.4% ATTRV30M). During follow-up, 73.9% of AA and 54.8% of AL patients progressed to end-stage renal disease, and 79.7% of AA and 77.4% of AL died; median overall survival was 66.0 (95% CI, 33.0–99.0) and 18.0 (95% CI, 9.3–26.7) months (p = 0.025), respectively. There were no significant differences in renal outcome and survival on dialysis between these two types. In multivariate analysis, cardiac involvement at presentation (HR 6.26 [95% CI, 2.89–13.56]) and estimated glomerular filtration rate 2 (HR 2.05 [95% CI, 1.06–3.99]) independently influenced AA and AL amyloidosis survival. Cardiac involvement at presentation was an independent predictor of death (HR 9.65 [95% CI, 2.91–31.95]) and early mortality in AL amyloidosis. Conclusions: In Portugal, AA amyloidosis and related chronic infections are still relevant. Regarding AL amyloidosis, the low incidence and advanced disease at presentation result from missed and erroneous diagnoses, leading to delayed referrals and poor outcomes in these patients.
- Open Access
- 17 January 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (2) , 457
Could Bone Biomarkers Predict Bone Turnover after Kidney Transplantation?—A Proof-of-Concept Study
Aim: Bone disease after kidney transplant (KT) results from multiple factors, including previous bone and mineral metabolism disturbances and effects of transplant-related medications. New biomolecules have been recently associated with the development and progression of the chronic kidney disease–associated bone and mineral disorder (CKD-MBD). These include sclerostin and the soluble receptor activator of nuclear factor-kB ligand (sRANKL). Methods: To better understand the role of biomarkers in post-transplant bone disease, this study was designed to prospectively evaluate and correlate results from the histomorphometric analysis of bone biopsies after KT with emerging serum biomarkers of the CKD-MBD: sclerostin, Dickkopf-related protein 1 (Dkk-1), sRANKL and osteo-protegerin (OPG). Results: Our data shows a significant increase in plasma levels of bioactive sclerostin after KT accompanied by a significant reduction in plasma levels of Dkk-1, suggesting a promotion of the inhibition of bone formation by osteoblasts through the activation of these inhibitors of the Wnt signaling pathway. In addition, we found a significant increase in plasma levels of free sRANKL after KT accompanied by a significant reduction in plasma levels of its decoy receptor OPG, suggesting an enhanced bone resorption by osteoclasts mediated by this mechanism. Conclusions: Taken together, these results suggest that the loss of bone volume observed after KT could be explain mainly by the inhibition of bone formation mediated by sclerostin accompanied by an enhanced bone resorption mediated by sRANKL.
- 17 January 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (2) , 457
Open AccessCould Bone Biomarkers Predict Bone Turnover after Kidney Transplantation?—A Proof-of-Concept Study
Aim: Bone disease after kidney transplant (KT) results from multiple factors, including previous bone and mineral metabolism disturbances and effects of transplant-related medications. New biomolecules have been recently associated with the development and progression of the chronic kidney disease–associated bone and mineral disorder (CKD-MBD). These include sclerostin and the soluble receptor activator of nuclear factor-kB ligand (sRANKL). Methods: To better understand the role of biomarkers in post-transplant bone disease, this study was designed to prospectively evaluate and correlate results from the histomorphometric analysis of bone biopsies after KT with emerging serum biomarkers of the CKD-MBD: sclerostin, Dickkopf-related protein 1 (Dkk-1), sRANKL and osteo-protegerin (OPG). Results: Our data shows a significant increase in plasma levels of bioactive sclerostin after KT accompanied by a significant reduction in plasma levels of Dkk-1, suggesting a promotion of the inhibition of bone formation by osteoblasts through the activation of these inhibitors of the Wnt signaling pathway. In addition, we found a significant increase in plasma levels of free sRANKL after KT accompanied by a significant reduction in plasma levels of its decoy receptor OPG, suggesting an enhanced bone resorption by osteoclasts mediated by this mechanism. Conclusions: Taken together, these results suggest that the loss of bone volume observed after KT could be explain mainly by the inhibition of bone formation mediated by sclerostin accompanied by an enhanced bone resorption mediated by sRANKL.
- Open Access
- 14 July 2020
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 34 (2)
Kidney-induced osteoporosis: a new entity with a novel therapeutic approach
- 14 July 2020
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 34 (2)
Open AccessKidney-induced osteoporosis: a new entity with a novel therapeutic approach
- 8 May 2020
- Published by Springer Nature
- p. 155-173
The Role of the Old and the New Calcimimetic Agents in Chronic Kidney Disease-Mineral and Bone Disorder
- 8 May 2020
- Published by Springer Nature
- p. 155-173
The Role of the Old and the New Calcimimetic Agents in Chronic Kidney Disease-Mineral and Bone Disorder
- Open Access
- 8 December 2017
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 11 (1) , 80-88
Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
Secondary hyperparathyroidism (SHPT) is associated with increased bone turnover, risk of fractures, vascular calcifications, and cardiovascular and all-cause mortality. The classical treatment for SHPT includes active vitamin D compounds and phosphate binders. However, achieving the optimal laboratory targets is often difficult because vitamin D sterols suppress parathyroid hormone (PTH) secretion, while also promoting calcium and phosphate intestinal absorption. Calcimimetics increase the sensitivity of the calcium-sensing receptor, so that even with lower levels of extracellular calcium a signal can still exist, leading to a decrease of the set-point for systemic calcium homeostasis. This enables a decrease in plasma PTH levels and, consequently, of calcium levels. Cinacalcet was the first calcimimetic to be approved for clinical use. More than 10 years since its approval, cinacalcet has been demonstrated to effectively reduce PTH and improve biochemical control of mineral and bone disorders in chronic kidney patients. Three randomized controlled trials have analysed the effects of treatment with cinacalcet on hard clinical outcomes such as vascular calcification, bone histology and cardiovascular mortality and morbidity. However, a final conclusion on the effect of cinacalcet on hard outcomes remains elusive. Etelcalcetide is a new second-generation calcimimetic with a pharmacokinetic profile that allows thrice-weekly dosing at the time of haemodialysis. It was recently approved in Europe, and is regarded as a second opportunity to improve outcomes by optimizing treatment for SHPT. In this review, we summarize the impact of cinacalcet with regard to biochemical and clinical outcomes. We also discuss the possible implications of the new calcimimetic etelcalcetide in the quest to improve outcomes.
- 8 December 2017
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 11 (1) , 80-88
Open AccessOld and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
Secondary hyperparathyroidism (SHPT) is associated with increased bone turnover, risk of fractures, vascular calcifications, and cardiovascular and all-cause mortality. The classical treatment for SHPT includes active vitamin D compounds and phosphate binders. However, achieving the optimal laboratory targets is often difficult because vitamin D sterols suppress parathyroid hormone (PTH) secretion, while also promoting calcium and phosphate intestinal absorption. Calcimimetics increase the sensitivity of the calcium-sensing receptor, so that even with lower levels of extracellular calcium a signal can still exist, leading to a decrease of the set-point for systemic calcium homeostasis. This enables a decrease in plasma PTH levels and, consequently, of calcium levels. Cinacalcet was the first calcimimetic to be approved for clinical use. More than 10 years since its approval, cinacalcet has been demonstrated to effectively reduce PTH and improve biochemical control of mineral and bone disorders in chronic kidney patients. Three randomized controlled trials have analysed the effects of treatment with cinacalcet on hard clinical outcomes such as vascular calcification, bone histology and cardiovascular mortality and morbidity. However, a final conclusion on the effect of cinacalcet on hard outcomes remains elusive. Etelcalcetide is a new second-generation calcimimetic with a pharmacokinetic profile that allows thrice-weekly dosing at the time of haemodialysis. It was recently approved in Europe, and is regarded as a second opportunity to improve outcomes by optimizing treatment for SHPT. In this review, we summarize the impact of cinacalcet with regard to biochemical and clinical outcomes. We also discuss the possible implications of the new calcimimetic etelcalcetide in the quest to improve outcomes.
- 1 November 2017
- Published by Elsevier in Kidney International
- Vol. 92 (5) , 1084-1099
Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats
- 1 November 2017
- Published by Elsevier in Kidney International
- Vol. 92 (5) , 1084-1099
Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats
- Open Access
- 7 July 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (7) , e0179868
Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients
In dialysis patients, there is an increasing evidence that altered bone metabolism is associated with cardiovascular calcifications. The main objective of this study was to analyse, in hemodialysis patients, the relationships between bone turnover, mineralization and volume, evaluated in bone biopsies, with a plain X-ray vascular calcification score. In a cross-sectional study, bone biopsies and evaluation of vascular calcifications were performed in fifty hemodialysis patients. Cancellous bone volume, mineralized bone volume, osteoid volume, activation frequency, bone formation rate/bone surface, osteoid thickness and mineralization lag time were determined by histomorphometry. Vascular calcifications were assessed by the simple vascular calcification score (SVCS) in plain X-Ray of pelvis and hands and, for comparison, by the Agatston score in Multi-Slice Computed Tomography (MSCT). SVCS≥3 was present in 20 patients (40%). Low and high bone turnover were present in 54% and 38% of patients, respectively. Low bone volume was present in 20% of patients. In multivariable analysis, higher age (p = 0.015) and longer hemodialysis duration (p = 0.017) were associated with SVCS≥3. Contrary to cancellous bone volume, the addition to this model of mineralized bone volume (OR = 0.863; 95%CI: 0.766, 0.971; p = 0.015), improved the performance of the model. For each increase of 1% in mineralized bone volume there was a 13.7% decrease in the odds of having SVCS≥3 (p = 0.015). An Agatston score>400 was observed in 80% of the patients with a SVCS≥3 versus 4% of patients with a SVCS<3, (p<0.001). Higher mineralized bone volume was associated with a lower plain X-ray vascular calcification. This study corroborates the hypothesis of the existence of a link between bone and vessel and reinforces the clinical utility of this simple and inexpensive vascular calcification score in dialysis patients.
- 7 July 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (7) , e0179868
Open AccessHigher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients
In dialysis patients, there is an increasing evidence that altered bone metabolism is associated with cardiovascular calcifications. The main objective of this study was to analyse, in hemodialysis patients, the relationships between bone turnover, mineralization and volume, evaluated in bone biopsies, with a plain X-ray vascular calcification score. In a cross-sectional study, bone biopsies and evaluation of vascular calcifications were performed in fifty hemodialysis patients. Cancellous bone volume, mineralized bone volume, osteoid volume, activation frequency, bone formation rate/bone surface, osteoid thickness and mineralization lag time were determined by histomorphometry. Vascular calcifications were assessed by the simple vascular calcification score (SVCS) in plain X-Ray of pelvis and hands and, for comparison, by the Agatston score in Multi-Slice Computed Tomography (MSCT). SVCS≥3 was present in 20 patients (40%). Low and high bone turnover were present in 54% and 38% of patients, respectively. Low bone volume was present in 20% of patients. In multivariable analysis, higher age (p = 0.015) and longer hemodialysis duration (p = 0.017) were associated with SVCS≥3. Contrary to cancellous bone volume, the addition to this model of mineralized bone volume (OR = 0.863; 95%CI: 0.766, 0.971; p = 0.015), improved the performance of the model. For each increase of 1% in mineralized bone volume there was a 13.7% decrease in the odds of having SVCS≥3 (p = 0.015). An Agatston score>400 was observed in 80% of the patients with a SVCS≥3 versus 4% of patients with a SVCS<3, (p<0.001). Higher mineralized bone volume was associated with a lower plain X-ray vascular calcification. This study corroborates the hypothesis of the existence of a link between bone and vessel and reinforces the clinical utility of this simple and inexpensive vascular calcification score in dialysis patients.